We were delighted to catch up with Dr Qi Cui (Scheie Eye Institute, University of Pennsylvania, PA, USA), who told us about her research on the GLP-1R agonist NLY01 and the next steps for clinical development.
- What is NLY01 and what is the rationale for its use in glaucoma therapy? (00:20)
- Could you give us an overview of your study and its findings? (01:31)
- What will be the next steps in the clinical development of NLY01? (02:46)
Speaker Disclosure: Qi Cui discloses the following: Patent (pending): Penn Center for Innovation; Sponsored Research: Neuraly, Inc., NIH/NEI K08EY029765.
Support: Interview and filming supported by Touch Medical Media Ltd.
Filmed in coverage of AGS 2021.
Share this Video
Related Videos In Glaucoma
Thomas V Johnson, AGS 2021: Current Status and Future Challenges of Stem Cell-based Retinal Ganglion Cell Transplantation in Glaucoma Therapy
We were delighted to speak with Dr Thomas V Johnson (Wilmer Eye Institute, Johns Hopkins University, Baltimore, MD, USA) and find out his thoughts on the current status and future challenges of stem cell-based retinal ganglion cell transplantation in glaucoma therapy, and the challenges and opportunities of the online format of this year’s virtual meeting. […]
Thomas V Johnson, AGS 2021: Cell Intrinsic and Microenvironmental Modulators of Human Stem Cell Derived RGC Survival and Retinal Integration Following Transplantation
It was a pleasure to speak to Dr Thomas V Johnson (Wilmer Eye Institute, Johns Hopkins University, Baltimore, MD, USA) about his presentation at AGS 2021, investigating cell intrinsic and microenvironmental modulators of retinal ganglion cell survival and retinal integration following transplantation. Questions What were the aims and design of your study investigating cell intrinsic […]
Qi Cui, AGS 2021: Promising Novel Therapies in Glaucoma and Meeting Highlights
It was great to speak with Dr Qi Cui (Scheie Eye Institute, University of Pennsylvania, PA, USA) about her views on the most promising novel therapies targeting risk factors other than intraocular pressure in glaucoma, and her highlights from AGS21. Questions What are the most promising novel therapies targeting risk factors other than intraocular pressure […]
Journal articles and more to your inbox
Get the latest clinical insights from touchOPHTHALMOLOGYSign me up!